前列地尔治疗慢性肾脏病的临床疗效观察与分析

摘要

目的：观察前列地尔治疗慢性肾脏病(CKD)的临床疗效。方法76例CKD患者，随机分为对照组(40例)和观察组(36例)。对照组给予常规治疗，观察组在常规治疗基础上给予前列地尔治疗。治疗前后比较两组血肌酐(SCr)、血尿素氮(BUN)、24 h尿蛋白定量、D-二聚体(D-D)的变化。结果治疗后，观察组SCr(186.6±19.4)µmol/L、BUN(8.2±1.8)mmol/L、24 h尿蛋白定量(1.96±0.17)g/24 h、D-D (0.68±0.08)mg/L优于对照组，差异均具有统计学意义(P<0.05)。结论前列地尔可以有效减少蛋白尿，改善高凝状态，保护肾功能，值得临床推广应用。%Objective To observe clinical effect by alprostadil in the treatment of chronic kidney disease (CKD).Methods A total of 76 CKD patients were randomly divided into control group (40 cases) and observation group (36 cases). The control group received conventional therapy, and the observation group received additional alprostadil for treatment. Comparison was madeon changes of serum creatinine (SCr), blood urea nitrogen (BUN), 24 h urine protein quantitation, and D-dimer (D-D) before and after treatment between the two groups.Results After treatment, the observation group had all better Scr as (186.6±19.4) µmol/L, BUN as (8.2±1.8) mmol/L, 24 h urine protein quantitation as (1.96±0.17) g/24 h and D-D as (0.68±0.08) mg/L than those in the control group. Their differences all had statistical significance (P<0.05).Conclusion Alprostadil can effectively reduce proteinuria, improve hypercoagulable state and protect kidney function. It is worth clinical promotion and application.